Epilepsy in special situations

• Many people with epilepsy are never seen in a hospital for a first seizure, yet every first seizure needs urgent specialist assessment within two weeks and a careful search for reversible causes.
• Antiseizure medication (ASM) is started once epilepsy is diagnosed, and the risks of treatment are balanced against the risks of further seizures at every review.
• Several commonly used ASMs make hormonal contraception less reliable, and oestrogen-containing contraception can speed the breakdown of lamotrigine; a non-interacting method or an intrauterine device is often safer.
• Two agents carry strict pregnancy limits: sodium valproate must not be started in people under 55 unless two specialists agree, and topiramate should not be used in pregnancy for any indication except epilepsy with no other suitable treatment, with contraception for four weeks after the last dose. ^[2][3]
• Sudden unexpected death in epilepsy (SUDEP) is rare but real; seizure control and medication adherence are the main modifiable protections.
• Driving rules are strict and separate: twelve months seizure-free for group 1 (cars and motorcycles) with epilepsy, with shorter or longer rules for first or sleep-only seizures. ^[4]
• Stopping an ASM is reasonable after two seizure-free years only after an individualised risk assessment and a supervised taper.

By the end of this page you should be able to:

1. Describe how a first seizure should be assessed and referred, and which tests are used.
2. Explain how ASMs and hormonal contraception interact in both directions, and choose a suitable contraceptive approach.
3. Outline the MHRA limits on sodium valproate and on topiramate, including the Pregnancy Prevention Programme.
4. Counsel a patient about SUDEP risk and its modifiable factors.
5. State the DVLA driving rules after a first, recurrent or sleep seizure, and during ASM withdrawal.
6. Decide when an ASM may be withdrawn and describe a safe taper.
7. Outline pregnancy planning, folate use and monitoring in epilepsy.

This page collects the parts of epilepsy care that do not fit the routine "start one drug and review annually" pathway: the first-seizure clinic; contraception and pregnancy; the strict UK and MHRA limits on valproate and topiramate; counselling about SUDEP; the UK driving rules; and the supervised withdrawal of an ASM when a person has been seizure-free. It is written for a medical student meeting these situations for the first time. The details below come from NICE guideline NG217 (2022, last updated August 2026) ^[1], MHRA safety advice on valproate and topiramate ^[2][3], DVLA guidance on neurological disorders (last updated November 2025) ^[4], and ILAE reports on pregnancy management ^[5]. Advice that is specific to the United Kingdom is marked with a regional note; the principles, not the local forms, apply everywhere.

A first seizure is frightening, and the next one is unpredictable. NICE guidance is that children, young people and adults are referred urgently for an assessment within two weeks of a first suspected seizure ^[1]. Adults go to a clinician with expertise in assessing first seizures and epilepsy; children to a paediatrician with that expertise. A recurrence after a period of remission also triggers an urgent referral within two weeks ^[1].

Take a detailed history from the person, and from family or carers, and use eyewitness accounts or video where possible ^[1]. Examine fully. Perform a 12-lead ECG to look for cardiac causes that can mimic a seizure ^[1]. Be aware that metabolic disturbance, including hypoglycaemia, can produce seizures ^[1]. Offer brain imaging if an underlying structural cause is suspected ^[1]. If the history suggests an epileptic seizure, consider a routine awake EEG to support diagnosis and classify seizure type; do not use EEG to exclude epilepsy ^[1]. If an EEG is requested after a first seizure it should be done as soon as possible, ideally within 72 hours ^[1]. Where ordinary EEGs are normal and uncertainty persists, consider sleep-deprived or ambulatory EEG.

Carry out an individualised assessment of the risk of a second seizure ^[1]. In adults, check modifiable factors that raise risk: an underlying mental health problem such as depression, anxiety or psychosis; alcohol or substance misuse; vascular risk factors such as diabetes, hypertension and atrial fibrillation; and sepsis ^[1]. Discuss these risks with the person and how they can be modified ^[1].

After a first seizure, give information about how to recognise a further seizure, emergency care, safety measures and who to contact if another seizure occurs while waiting for assessment ^[1]. In children the parent or carer should know how to self-refer urgently if a further seizure occurs ^[1].

Whether or not to start an ASM after a first unprovoked seizure depends on the assessment: an examination showing neurological deficit, an EEG with unequivocal epileptic activity, brain imaging showing a structural abnormality, or the person deciding that the risk is unacceptable ^[1]. Otherwise treatment starts once epilepsy is diagnosed.

Unplanned pregnancies are common in women with epilepsy, and several ASMs interact with hormonal contraception in both directions ^[6]. Choosing a contraceptive method needs as much attention as choosing the ASM.

Some ASMs induce hepatic enzymes, especially cytochrome P450 3A4, and speed the breakdown of the oestrogen and progestogen in combined hormonal contraception ^[6]. The enzyme-inducing group includes carbamazepine, phenytoin, phenobarbital and primidone as strong inducers, plus oxcarbazepine, eslicarbazepine, topiramate, felbamate, rufinamide, clobazam and perampanel as weaker inducers ^[6]. Carbamazepine, oxcarbazepine, phenytoin and topiramate are specifically flagged in NICE guidance as impairing the effectiveness of hormonal contraceptives ^[1]. Lamotrigine is a weak inducer at doses of about 300 mg daily or more; perampanel at 12 mg or more; topiramate at 200 mg daily or more ^[6]. Valproic acid does not change the effectiveness of hormonal contraceptives ^[6].

NICE also reminds clinicians that oestrogen-containing hormonal contraceptives and hormone replacement therapy can reduce the effectiveness of lamotrigine, because oestrogen increases its glucuronidation ^[1].

The oestrogen component of combined oral contraception (ethinylestradiol) can speed the elimination of ASMs metabolised by glucuronidation. Lamotrigine levels fall by about 50 percent within one week of co-administration ^[6], and valproic acid levels also fall significantly ^[6]. If a combined pill is needed in a woman taking lamotrigine or valproate, monitor ASM levels closely and adjust the dose to the pre-treatment level, or choose a non-interacting method.

A combined oral contraceptive or the progestogen implants may fail when used with an enzyme-inducing ASM, through both oral and non-oral routes ^[6]. Safer choices for women on enzyme-inducing ASMs include a copper intrauterine device, a progestogen-releasing intrauterine device, progestogen-only emergency contraception with a higher dose where appropriate, or a barrier method in addition to the hormonal method ^[6]. Depot medroxyprogesterone acetate is effective but has a less favourable side-effect profile and can reduce bone mineral density; with enzyme-inducing ASMs such as clobazam it may need to be given every 8 to 10 weeks rather than every 12 ^[6]. Where possible, change the ASM rather than compromise contraception, or move to a non-enzyme-inducing drug ^[6].

The table summarises the commonly taught classification.

Stopping an ASM is appealing: many people who are seizure-free dislike daily tablets and worry about long-term effects. Withdrawal should be discussed at every review, not as a sudden decision ^[1]. The evidence is that relapse is common, and many people who relapse do not regain the same control.

After a person has been seizure-free for two years, carry out an individualised assessment of the risk of recurrence, done by an epilepsy specialist if there is any doubt ^[1]. Base the decision on the individualised risk, including the risk of SUDEP where appropriate, on lifestyle and on practical matters such as driving ^[1]. Factors that raise recurrence risk include a longer history of epilepsy, many seizures before remission, short seizure-free interval before withdrawal, older age at onset, a low IQ, previous febrile seizures, marked EEG abnormalities and a non-self-limiting syndrome. The individual risk can be estimated with published prediction tools.

If withdrawal is chosen, agree a plan. Reduce one drug at a time; most drugs are reduced gradually over at least three months, and benzodiazepines and barbiturates are usually tapered over a longer period to reduce withdrawal symptoms ^[1]. If seizures recur during or after withdrawal, reverse the last dose reduction and seek specialist advice ^[1]. Do not stop suddenly or unsupervised. Withdrawal also carries a six-month ban on driving, from the start of reduction until six months after the last dose (see driving below). ^[4]

This section is United Kingdom specific; other countries have their own licensing rules and waiting periods.

The DVLA treats epilepsy as two or more unprovoked seizures more than 24 hours but less than five years apart ^[4]. An isolated seizure is one or more unprovoked seizures in 24 hours occurring after at least five seizure-free years.

With established epilepsy, driving must stop and the DVLA must be notified. Driving can resume after 12 months free of all seizures, including minor seizures, auras and absence-type events ^[4]. A single first seizure allows resumption after six months if there are no clinical or investigation factors suggesting a high risk of recurrence, and after twelve months if there is an underlying cause that increases risk ^[4]. Seizures occurring only during sleep can allow relicensing after one year in certain patterns, including a three-year pattern of sleep-only seizures ^[4]. Seizures that do not affect consciousness or function may allow relicensing after one year if they are the only type ever experienced ^[4].

If a seizure occurs within six months of a documented, doctor-advised reduction or withdrawal of medication, the rules allow earlier relicensing once the previously effective medication has been reinstated for six months and the person has been seizure-free for six months ^[4].

During withdrawal of ASM, a person must not drive during the reduction or for six months afterwards ^[4].

Requirements are much stricter: ten years seizure-free without any ASM treatment, a full ordinary licence, and no continuing increased risk of seizures ^[4]. After a single seizure the rule is five years seizure-free without medication, with a neurologist's recent assessment showing a low annual risk ^[4].

A driver must notify the DVLA and stop driving immediately after any seizure, and failure to notify can bring a fine of up to 1,000 pounds ^[4]. Any warning signs must be heeded: a pattern established for one seizure type is lost if a different type occurs, and the concession is lost ^[4]. People who have dissociative (non-epileptic) seizures may be relicensed after an event-free period of three months for group 1, or after six months with a specialist review for group 2 ^[4].

Pregnancy in epilepsy is usually successful: most women with epilepsy have uneventful pregnancies and healthy babies ^[5]. The task is to balance the risks of uncontrolled seizures, especially convulsive seizures, against the risks of ASMs to the fetus ^[5]. Address this well before conception, ideally reviewing the indication, the drug and the dose, and completing any change of ASM in time to confirm control before pregnancy occurs ^[5].

Contraceptive planning is part of pre-conception care: roughly 65 percent of pregnancies in women with epilepsy are unplanned in survey data, and only a quarter of at-risk women report having been counselled about contraception by their neurologist ^[6]. Use the least interacting method, follow ASM levels where a combined pill is used with lamotrigine or valproate, and use a folate supplement (doses in guidelines range from 0.4 mg daily to 4 mg or more) ^[5].

Take folate supplementation before conception; neural tube defects occur early, before most women know they are pregnant ^[6]. Avoid valproate and carbamazepine where possible if there is a family history of neural tube defects ^[6]. Aim for the lowest effective dose and monotherapy where possible, and document a serum concentration before pregnancy when monitoring is available, so it can be matched later.

Pregnancy changes drug handling: renal clearance rises by 40 to 50 percent, and hepatic enzyme activity, especially glucuronidation, increases. Lamotrigine clearance can rise to more than 330 percent of baseline by 32 weeks in about 77 percent of women, with return to baseline within three weeks after delivery ^[6]. Levetiracetam, gabapentin, pregabalin, topiramate and zonisamide are cleared renally and may need dose adjustment; monitor blood levels monthly where possible, and return dosing towards pre-pregnancy levels in the first days after birth ^[1][6]. Drugs bound to albumin, such as phenytoin, valproate and carbamazepine, can show a fall in total but not free concentration, so monitor free levels to avoid toxicity ^[6].

Epilepsy alone is not an indication for caesarean section; vaginal delivery is the norm ^[5]. Breastfeeding is generally safe with most ASMs and should be encouraged, with decisions made between the woman and her prescriber ^[1].

Sodium valproate is effective but carries the highest teratogenic risk among the common ASMs, in a dose-dependent way ^[5]. In women taking valproate during pregnancy, around 11 percent (one in nine) of babies has a birth defect, including neural tube and cardiac defects, and three to four in ten children have problems with early development ^[2]. There is an increased risk of autism spectrum disorder and a possible excess of ADHD ^[2]. Because of this, valproate must not be used in women and girls able to have children unless the conditions of the Pregnancy Prevention Programme are fulfilled ^[2]. ^[1]

UK rules for valproate:

• No one under 55 should be started on valproate (for either sex) unless two specialists independently consider and document that no other effective or tolerated treatment exists, or that reproductive risks do not apply ^[2].

• Girls and women able to have children must follow the Pregnancy Prevention Programme: signed annual risk acknowledgement, regular risk discussion, and highly effective contraception ^[2].

• Male patients under 55 starting valproate complete a male risk acknowledgement form; valproate can cause reversible male infertility and possible testicular toxicity ^[2].

• As a precaution, men taking valproate and their partners should use effective contraception during treatment; the observed risk relates to exposure in the three months before conception ^[2].

• Men taking valproate who are planning a family within the next year should be referred to an epilepsy specialist team for review of medication options ^[1].

• Do not stop valproate suddenly; no one should stop without specialist advice, because seizure control matters ^[2].

• In men taking valproate for three months before conception, about five in every hundred children may have neurodevelopmental conditions, although causation is not established ^[2]. Valproate and hormonal contraception are another reason for monitoring, because hormonal contraception can lower valproate levels ^[6].

• Two specialist signatures are required at initiation only; annual review needs one specialist ^[2].

Topiramate is contraindicated in pregnancy for migraine prevention and for epilepsy unless there is no other suitable treatment ^[3]. It is contraindicated in women of childbearing potential unless the conditions of its own Pregnancy Prevention Programme are met: highly effective contraception, exclusion of pregnancy before starting, and documented awareness of risk ^[3]. The risk picture is:

• Congenital malformations in about 4 to 9 per 100 babies, compared with about 1 to 3 per 100 in the general population, and the risk appears dose-related, with no dose below which risk is absent ^[3].
• High rates of babies being born small for gestational age, about 18 per 100 ^[3].
• An approximately two to three fold increase in risk of intellectual disability, autism spectrum disorder and ADHD ^[3].

Women on topiramate should use effective contraception during treatment and for at least four weeks after the last dose. Topiramate interacts with some hormonal contraceptives; check the Faculty of Sexual and Reproductive Healthcare guidance and individual drug advice ^[3]. New patients need a negative pregnancy test and a signed risk awareness form; existing patients should be invited in for review, with the form completed at initiation and annually ^[3]. As with valproate, topiramate should not be stopped without medical advice if it is being used for epilepsy, because seizures may worsen.

Sudden unexpected death in epilepsy (SUDEP) is a death in a person with epilepsy that is not due to status epilepticus, trauma or drowning and where no other cause is found. Epilepsy carries an increased risk of premature death, including SUDEP ^[1]. Discuss the individual risk of epilepsy-related death, including SUDEP, with the person and family from the time of diagnosis ^[1]. For young children, the discussion is with parents or carers.

Potentially modifiable risk factors include non-adherence to medication, alcohol or drug misuse, having focal to bilateral or generalised tonic-clonic seizures, uncontrolled seizures, living alone and sleeping alone without supervision ^[1]. Other factors that raise risk include previous brain injury, central nervous system infection, metastatic cancer, previous stroke and abnormal neurological examination findings ^[1].

Practical measures to reduce risk:

• Support strict adherence to ASMs; uncontrolled seizures increase the risk of epilepsy-related death, especially with generalised or focal to bilateral tonic-clonic seizures ^[1].
• Review night-time supervision for people with seizures during sleep, for example using a night monitor where assessment shows higher risk ^[1].
• Discuss modifiable factors, including alcohol and substance misuse ^[1].
• Keep annual review in those at higher risk, such as drug-resistant epilepsy, high SUDEP risk, learning disability or high-risk teratogenic therapy ^[1].

Counselling should be honest but proportionate: SUDEP is uncommon and good seizure control is the most important protection. Do not withhold the information; most patients want it and it supports adherence.

• Pre-conception review and structured contraception counselling are often lacking, particularly in resource-poor settings, where unplanned pregnancy rates are higher.
• Where blood-level monitoring and brain imaging are unavailable, rely on clinical seizure control, history and a documented baseline concentration where any monitoring is possible, and use national formularies for safe drug choice.
• Copper intrauterine devices and barrier methods are suitable choices for women on enzyme-inducing ASMs and need no special laboratory support.
• Valproate and phenobarbital may be the most available and affordable agents; counsel carefully about pregnancy risk where alternatives are not accessible, and use the MHRA Pregnancy Prevention Programme steps even when the forms differ locally.
• Folate 0.4 mg daily is cheap and should be offered to women of childbearing potential on ASMs even where higher doses are not stocked ^[5].

Refer any woman or girl planning pregnancy or already pregnant to an epilepsy specialist team for ASM review, and share care with obstetric and primary care services. Refer men on valproate planning a family within the next year for medication review. Refer people with drug-resistant epilepsy, intolerable side effects or diagnostic uncertainty to tertiary epilepsy services

• Epilepsy is diagnosed clinically, supported by investigations; a first seizure needs urgent specialist assessment within two weeks ^[1].
• Start an ASM once epilepsy is confirmed; after a first unprovoked seizure, treatment is guided by neurological deficit, epileptic EEG activity, a structural abnormality or the patient's choice ^[1].
• Ask about contraception at every visit. Enzyme-inducing ASMs such as carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, eslicarbazepine, topiramate (at 200 mg daily or more), rufinamide, felbamate, clobazam and perampanel (at 12 mg or more) can make hormonal contraception fail; use an intrauterine device or a barrier method instead ^[6].
• Oestrogen-containing contraception can roughly halve lamotrigine levels within a week, and also reduces valproate levels; monitor and adjust doses ^[6].
• Valproate has the highest teratogenic risk: about 11 percent birth defects and three or four in ten with early developmental problems. It must not be started in people under 55 unless two specialists agree, and girls and women able to have children need the Pregnancy Prevention Programme and highly effective contraception ^[2].
• Topiramate is contraindicated in pregnancy for migraine prevention and for epilepsy unless no other treatment suits; its pregnancy prevention rules include contraception for four weeks after the last dose ^[3].
• Lamotrigine and levetiracetam have a fairly low teratogenic potential among commonly used ASMs; aim for monotherapy and the lowest effective dose, especially before conception ^[6].
• Folate recommendations in guidelines vary from 0.4 mg daily to 4 mg or more; offer folate before conception, especially with carbamazepine or valproate exposure ^[5][6].
• Discuss SUDEP honestly from diagnosis: non-adherence, alcohol or drug misuse, convulsive seizures, uncontrolled seizures, living or sleeping alone are modifiable risks; night-time supervision and adherence reduce risk ^[1].
• In the UK, group 1 drivers must be seizure-free for 12 months with epilepsy; a single seizure needs six or twelve months; sleep-only seizures have special patterns; group 2 needs ten years seizure-free without medication ^[4].
• ASM withdrawal should follow at least two seizure-free years, an individualised specialist assessment, and a supervised taper of at least three months for most drugs, and during withdrawal driving is banned for the reduction plus six months ^[1][4].
• In pregnancy, ASM levels often fall, especially lamotrigine; monitor monthly where possible and adjust, and vaginal delivery with breastfeeding is usually appropriate ^[1][5][6].